1
|
Miyazawa K, Asano Y, Tabuchi M, Kako S, Kawatani M, Osada H, Maeda H, Goto S. Local administration of ReveromycinA ointment suppressed alveolar bone loss in mice. J Pharmacol Sci 2021; 147:40-47. [PMID: 34294371 DOI: 10.1016/j.jphs.2021.05.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Revised: 05/13/2021] [Accepted: 05/19/2021] [Indexed: 12/19/2022] Open
Abstract
ReveromycinA (RMA) was developed and is a unique agent for inhibiting osteoclast activity. In a previous study, we experimentally induced periodontal disease in a high-turnover osteoporosis osteoprotegerin-knockout mice (OPG KO) model and found that intraperitoneal administration of RMA inhibited alveolar bone resorption. We prepared a novel RMA-containing ointment for topical non-invasive administration in the oral cavity, in preparation for possible future clinical application. And we investigated whether this ointment can inhibit alveolar bone resorption in an experimental mouse model of periodontal disease. We examined wild-type (WT) and OPG KO mice ligated with wire around contact points on the left first and second molars to cause food impaction and induce experimental periodontal disease. RMA was administered three times a day. Using micro-computed tomography, we measured the volume of alveolar bone loss and also performed histological analysis. Our findings showed that localized administration of RMA containing ointment resulted in suppressed alveolar bone resorption, reduced osteoclast count, and lower immunostaining scores of inflammation sites compared with controls in both OPG KO and WT mice. Localized application of the specific osteoclast suppressor RMA in ointment form in the oral cavity could be a novel treatment for periodontitis that inhibits alveolar bone resorption locally.
Collapse
Affiliation(s)
- Ken Miyazawa
- Department of Orthodontics, School of Dentistry, Aichi Gakuin University, 2-11 Suemori-Dori, Chikusa-ku, Nagoya 464-8651, Aichi, Japan.
| | - Yuichiro Asano
- Department of Orthodontics, School of Dentistry, Aichi Gakuin University, 2-11 Suemori-Dori, Chikusa-ku, Nagoya 464-8651, Aichi, Japan.
| | - Masako Tabuchi
- Department of Orthodontics, School of Dentistry, Aichi Gakuin University, 2-11 Suemori-Dori, Chikusa-ku, Nagoya 464-8651, Aichi, Japan.
| | - Shunsuke Kako
- Department of Orthodontics, School of Dentistry, Aichi Gakuin University, 2-11 Suemori-Dori, Chikusa-ku, Nagoya 464-8651, Aichi, Japan.
| | - Makoto Kawatani
- Chemical Biology Research Group, RIKEN CSRS, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
| | - Hiroyuki Osada
- Chemical Biology Research Group, RIKEN CSRS, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
| | - Hatsuhiko Maeda
- Department of Oral Pathology, School of Dentistry, Aichi Gakuin University, 1-100 Kusumoto-Cho, Chikusa-ku, Nagoya 464-8650, Aichi, Japan.
| | - Shigemi Goto
- Department of Orthodontics, School of Dentistry, Aichi Gakuin University, 2-11 Suemori-Dori, Chikusa-ku, Nagoya 464-8651, Aichi, Japan.
| |
Collapse
|